121 related articles for article (PubMed ID: 38539051)
21. Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies.
Masanneck L; Rolfes L; Regner-Nelke L; Willison A; Räuber S; Steffen F; Bittner S; Zipp F; Albrecht P; Ruck T; Hartung HP; Meuth SG; Pawlitzki M
Mult Scler Relat Disord; 2022 Jul; 63():103927. PubMed ID: 35700670
[TBL] [Abstract][Full Text] [Related]
22. Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'.
Harel A; Sperling D; Petracca M; Ntranos A; Katz-Sand I; Krieger S; Lublin F; Wang Z; Liu Y; Inglese M
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):977-982. PubMed ID: 29549189
[TBL] [Abstract][Full Text] [Related]
23. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
24. CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.
Boylan MT; Crockard AD; McDonnell GV; Armstrong MA; Hawkins SA
J Neurol Sci; 1999 Aug; 167(2):79-89. PubMed ID: 10521545
[TBL] [Abstract][Full Text] [Related]
25. VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis.
Miletic-Drakulic S; Miloradovic I; Jankovic V; Azanjac-Arsic A; Lazarevic S
Sensors (Basel); 2022 Nov; 22(22):. PubMed ID: 36433445
[TBL] [Abstract][Full Text] [Related]
26. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
[TBL] [Abstract][Full Text] [Related]
27. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
[TBL] [Abstract][Full Text] [Related]
29. Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.
Ozakbas S; Piri Cinar B; Baba C; Kosehasanogullari G; Sclerosis Research Group M
Acta Neurol Scand; 2022 May; 145(5):557-564. PubMed ID: 35043388
[TBL] [Abstract][Full Text] [Related]
30. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Collura F; Bazzurri V; Fiore A; Granella F
J Neurol Sci; 2020 Jul; 414():116827. PubMed ID: 32289575
[TBL] [Abstract][Full Text] [Related]
31. The course of cervical spinal cord atrophy rate and its relationship with NEDA in relapsing remitting multiple sclerosis.
Cilingir V; Akdeniz H
Acta Neurol Belg; 2022 Apr; 122(2):345-355. PubMed ID: 33475987
[TBL] [Abstract][Full Text] [Related]
32. Correlation of selected serum protein levels with the degree of disability and NEDA-3 status in multiple sclerosis phenotypes.
Lamancová P; Urban P; Mašlanková J; Rabajdová M; Mareková M
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3933-3941. PubMed ID: 35731063
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
Amato MP; Bergamaschi R; Centonze D; Mirabella M; Marfia GA; Totaro R; Lus G; Brescia Morra V; Aguglia U; Comi C; Cavalla P; Zaffaroni M; Rovaris M; Grimaldi LM; Leoni S; Malucchi S; Baldi E; Romano M; Falcini M; Perini P; Assetta M; Portaccio E; Sommacal S; Olivieri N; Parodi F; Todaro DS; Grassivaro N; Farina A; Mondino MM; Filippi M; Trojano M
J Neurol; 2023 Oct; 270(10):4687-4696. PubMed ID: 37405689
[TBL] [Abstract][Full Text] [Related]
34. Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod.
Diem L; Nedeltchev K; Kahles T; Achtnichts L; Findling O
Ther Adv Neurol Disord; 2018; 11():1756286418791103. PubMed ID: 30116299
[TBL] [Abstract][Full Text] [Related]
35. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Eur J Neurol; 2022 Apr; 29(4):1106-1116. PubMed ID: 34927308
[TBL] [Abstract][Full Text] [Related]
36. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
Balabanov R; Lisak D; Beaumont T; Lisak RP; Dore-Duffy P
Clin Diagn Lab Immunol; 2001 Nov; 8(6):1196-203. PubMed ID: 11687463
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis.
Prosperini L; Ruggieri S; Haggiag S; Tortorella C; Pozzilli C; Gasperini C
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34373345
[TBL] [Abstract][Full Text] [Related]
38. Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis.
Haschka D; Tymoszuk P; Bsteh G; Petzer V; Berek K; Theurl I; Berger T; Weiss G
Front Immunol; 2020; 11():594. PubMed ID: 32411125
[TBL] [Abstract][Full Text] [Related]
39. Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis.
Canto-Gomes J; Silva CS; Rb-Silva R; Boleixa D; da Silva AM; Cheynier R; Costa P; González-Suárez I; Correia-Neves M; Cerqueira JJ; Nobrega C
Front Immunol; 2022; 13():901165. PubMed ID: 35711452
[TBL] [Abstract][Full Text] [Related]
40. The evolution of "No Evidence of Disease Activity" in multiple sclerosis.
Lu G; Beadnall HN; Barton J; Hardy TA; Wang C; Barnett MH
Mult Scler Relat Disord; 2018 Feb; 20():231-238. PubMed ID: 29579629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
